Literature DB >> 17315190

CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo.

Oliver M Grauer1, Stefan Nierkens, Erik Bennink, Liza W J Toonen, Louis Boon, Pieter Wesseling, Roger P M Sutmuller, Gosse J Adema.   

Abstract

The suppressive activity of regulatory T cells (Treg) has been implicated as an important factor limiting immune mediated destruction of tumor cells. However, not much is known about the presence and function of Treg within tumors. Here we show in a syngeneic murine glioma model a time-dependent accumulation of CD4+FoxP3+ Treg in brain tumors. Further analysis revealed a time-dependent upregulation of CD25, CTLA-4, GITR and CXCR4 on intratumoral CD4+FoxP3+ Treg during tumor growth. Moreover, freshly isolated intratumoral Treg were highly suppressive when tested directly ex vivo. Treatment with anti-CD25 monoclonal antibodies (mAbs) significantly reduced the number of these highly suppressive CD4+FoxP3+ cells within the growing tumor and provoked a CD4 and CD8 T cell dependent destruction of the glioma cells. Combining Treg depletion with administration of blocking CTLA-4 mAbs further boosted glioma-specific CD4+ and CD8+ effector T cells as well as antiglioma IgG2a antibody titers resulting in complete tumor eradication without any signs of autoimmunity. These data illustrate that intratumoral accumulation and activation of CD4+FoxP3+ Treg act as a dominant immune escape mechanism for gliomas and underline the importance of controlling tumor-infiltrating Treg in glioma immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17315190     DOI: 10.1002/ijc.22607

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  99 in total

Review 1.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

Review 2.  Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.

Authors:  M P Bernard; S Bancos; P J Sime; R P Phipps
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

3.  Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Authors:  Jennifer E Kim; Mira A Patel; Antonella Mangraviti; Eileen S Kim; Debebe Theodros; Esteban Velarde; Ann Liu; Eric W Sankey; Ada Tam; Haiying Xu; Dimitrios Mathios; Christopher M Jackson; Sarah Harris-Bookman; Tomas Garzon-Muvdi; Mary Sheu; Allison M Martin; Betty M Tyler; Phuoc T Tran; Xiaobu Ye; Alessandro Olivi; Janis M Taube; Peter C Burger; Charles G Drake; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

Review 4.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 5.  Dendritic cell based vaccination strategy: an evolving paradigm.

Authors:  Anna C Filley; Mahua Dey
Journal:  J Neurooncol       Date:  2017-04-22       Impact factor: 4.130

Review 6.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.

Authors:  Daniel Dubinski; Johannes Wölfer; Martin Hasselblatt; Tilman Schneider-Hohendorf; Ulrich Bogdahn; Walter Stummer; Heinz Wiendl; Oliver M Grauer
Journal:  Neuro Oncol       Date:  2015-11-17       Impact factor: 12.300

Review 8.  Dendritic-cell- and peptide-based vaccination strategies for glioma.

Authors:  Ryuya Yamanaka
Journal:  Neurosurg Rev       Date:  2009-02-13       Impact factor: 3.042

9.  A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma.

Authors:  Marie-Denise Poirier; Houda Haban; Abdeljabar El Andaloussi
Journal:  J Oncol       Date:  2010-03-21       Impact factor: 4.375

Review 10.  DNA vaccines: developing new strategies against cancer.

Authors:  Daniela Fioretti; Sandra Iurescia; Vito Michele Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.